MedTrace Logo

Safety and Efficacy of SA09012 in Asthma

NCT01740986 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 225

Last updated 2015-11-16

No results posted yet for this study

Summary

Clinical Study to Evaluate the Efficacy, Dose-response and Safety of SA09012 in Bronchial Asthma Patients

Conditions

  • Mild to Moderate Bronchial Asthma

Interventions

DRUG

SA09012 Low dose

Tablet, b.i.d

DRUG

SA09012 High dose

Tablet, b.i.d

DRUG

Placebo

Tablet, b.i.d

Sponsors & Collaborators

  • SamA Pharmaceutical Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Young Kyoon Kim, MD · Seoul ST. Mary's Hospital The Catholic University of Korea

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2015-07-31
Completion
2015-11-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01740986 on ClinicalTrials.gov